Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.
COVID-19
SARS-CoV-2
antiviral drugs
favipiravir
lopinavir/ritonavir
remdesivir
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
08
2021
accepted:
09
11
2021
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
2
12
2021
Statut:
epublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel strain that causes acute respiratory illnesses known as coronavirus disease 2019 (COVID-19). Currently, there is limited information regarding the therapeutic management for this disease. Several studies have stated that antivirals drugs such as remdesivir, favipiravir, and lopinavir/ritonavir may potentially inhibit the virus from spreading to the host. The aim of this systematic review was to summarize the clinical effectiveness and safety of remdesivir, favipiravir, and lopinavir/ritonavir on COVID-19. The PubMed and Cochrane Library databases were searched up to July 2021 to identify eligible experimental randomized controlled trials on remdesivir, favipiravir, and lopinavir/ritonavir for COVID-19 patients. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. From 158 references, 15 studies were included in the review. The results showed that remdesivir has some potential benefits for hospitalized COVID-19 patients, as seen from clinical improvements such as faster recovery time, less duration of hospitalization, and fewer respiratory side effects among COVID-19 patients. However, the impact of remdesivir in reducing mortality remains uncertain. Treatment with favipiravir has shown promising improvement in the clinical status of COVID-19 patients, although the results suggested no significant differences in some clinical parameters such as length of hospitalizations and clinical recovery. A combination of favipiravir with other supportive therapy showed more favorable outcomes for COVID-19 patients. Furthermore, the use of lopinavir/ritonavir in COVID-19 patients reported no significant clinical improvement compared to standard care with notable adverse effect reactions. This study provides an overview of the evidence-based role of remdesivir, favipiravir, and lopinavir/ritonavir in the management of COVID-19. A thorough assessment of the benefit-risk profile in COVID-19 patients is urgently needed. The current review was based on very limited available data; therefore, further well-designed clinical trials are required.
Sections du résumé
BACKGROUND
BACKGROUND
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel strain that causes acute respiratory illnesses known as coronavirus disease 2019 (COVID-19). Currently, there is limited information regarding the therapeutic management for this disease. Several studies have stated that antivirals drugs such as remdesivir, favipiravir, and lopinavir/ritonavir may potentially inhibit the virus from spreading to the host.
OBJECTIVE
OBJECTIVE
The aim of this systematic review was to summarize the clinical effectiveness and safety of remdesivir, favipiravir, and lopinavir/ritonavir on COVID-19.
METHODS
METHODS
The PubMed and Cochrane Library databases were searched up to July 2021 to identify eligible experimental randomized controlled trials on remdesivir, favipiravir, and lopinavir/ritonavir for COVID-19 patients. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline.
RESULTS
RESULTS
From 158 references, 15 studies were included in the review. The results showed that remdesivir has some potential benefits for hospitalized COVID-19 patients, as seen from clinical improvements such as faster recovery time, less duration of hospitalization, and fewer respiratory side effects among COVID-19 patients. However, the impact of remdesivir in reducing mortality remains uncertain. Treatment with favipiravir has shown promising improvement in the clinical status of COVID-19 patients, although the results suggested no significant differences in some clinical parameters such as length of hospitalizations and clinical recovery. A combination of favipiravir with other supportive therapy showed more favorable outcomes for COVID-19 patients. Furthermore, the use of lopinavir/ritonavir in COVID-19 patients reported no significant clinical improvement compared to standard care with notable adverse effect reactions.
CONCLUSION
CONCLUSIONS
This study provides an overview of the evidence-based role of remdesivir, favipiravir, and lopinavir/ritonavir in the management of COVID-19. A thorough assessment of the benefit-risk profile in COVID-19 patients is urgently needed. The current review was based on very limited available data; therefore, further well-designed clinical trials are required.
Identifiants
pubmed: 34849001
doi: 10.2147/IJGM.S332458
pii: 332458
pmc: PMC8627269
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
8557-8571Informations de copyright
© 2021 Qomara et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Expert Rev Anti Infect Ther. 2021 Jun;19(6):679-687
pubmed: 33187459
PLoS One. 2020 Dec 10;15(12):e0243705
pubmed: 33301514
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
J Clin Med. 2021 Jan 13;10(2):
pubmed: 33451007
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
Curr Med Chem. 2022;29(1):4-18
pubmed: 34355678
Arch Virol. 2021 Mar;166(3):949-954
pubmed: 33492523
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Drug Saf. 2020 Jul;43(7):645-656
pubmed: 32468196
Pharmaceuticals (Basel). 2021 Jul 28;14(8):
pubmed: 34451833
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2575-2583
pubmed: 34347191
Virol Sin. 2020 Dec;35(6):685-698
pubmed: 32997322
J Pharm Pharm Sci. 2021;24:237-245
pubmed: 34048669
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Pharmacology. 2021;106(9-10):462-468
pubmed: 34515227
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Int J Infect Dis. 2021 Feb;103:62-71
pubmed: 33212256
JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
Microorganisms. 2020 Oct 20;8(10):
pubmed: 33092045
Eur Respir J. 2021 Apr 15;57(4):
pubmed: 33692120
Clin Exp Med. 2021 May;21(2):167-179
pubmed: 33128197
Biomed Pharmacother. 2021 Jan;133:110825
pubmed: 33378989
Int J Infect Dis. 2021 Jan;102:538-543
pubmed: 33181328
BMC Infect Dis. 2021 May 27;21(1):489
pubmed: 34044777
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):549-555
pubmed: 33506948
Sci Rep. 2021 Mar 31;11(1):7282
pubmed: 33790308
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
BMJ Open. 2021 Jun 24;11(6):e048416
pubmed: 34168031
JAMA Netw Open. 2021 Apr 1;4(4):e216468
pubmed: 33885775
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
Med. 2020 Dec 18;1(1):105-113.e4
pubmed: 32838353
Nat Rev Drug Discov. 2016 May;15(5):327-47
pubmed: 26868298
Clin Toxicol (Phila). 2021 Jul;59(7):644-647
pubmed: 33641562
JAMA. 2020 Feb 25;323(8):707-708
pubmed: 31971553
Theranostics. 2020 Jun 19;10(17):7821-7835
pubmed: 32685022
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
Int Immunopharmacol. 2021 Jun;95:107522
pubmed: 33735712
J Virus Erad. 2020 Apr 30;6(2):45-51
pubmed: 32405421
Eur J Pharm Sci. 2021 Feb 1;157:105631
pubmed: 33115675
Drug Res (Stuttg). 2021 Mar;71(3):166-170
pubmed: 33176367
Postgrad Med J. 2021 May;97(1147):312-320
pubmed: 32978337
Ann Intensive Care. 2020 Oct 6;10(1):131
pubmed: 33025225
Brief Bioinform. 2021 Mar 22;22(2):690-700
pubmed: 33057582
Molecules. 2021 Feb 13;26(4):
pubmed: 33668428
Annu Rev Control. 2021;52:587-601
pubmed: 34093069
Lancet. 2020 Oct 24;396(10259):1345-1352
pubmed: 33031764
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
BMC Med. 2020 Jun 25;18(1):191
pubmed: 32586336
J Antimicrob Chemother. 2021 Jul 15;76(8):1962-1968
pubmed: 33758946
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Int J Infect Dis. 2021 Jan;102:501-508
pubmed: 33130203
Explor Econ Hist. 2021 Jan;79:101381
pubmed: 33162564